-
公开(公告)号：US20190054164A1
公开(公告)日：2019-02-21
申请号：US16179990
申请日：2018-11-04
申请人： CureVac AG
IPC分类号： A61K39/155 , A61K47/69 , A61K47/59 , A61K47/64 , A61K39/00 , A61K39/12 , A61K39/145 , A61K45/06
CPC分类号： A61K39/155 , A61K39/00 , A61K39/12 , A61K39/145 , A61K45/06 , A61K47/59 , A61K47/6455 , A61K47/6921 , A61K2039/53 , A61K2039/54 , A61K2039/55 , A61K2039/55583 , A61K2039/572 , A61K2039/575 , A61K2039/6031 , A61K2039/622 , A61P31/16 , C12N2760/16134 , C12N2760/18534 , C12N2760/18571 , Y02A50/412 , Y02A50/486 , Y02A50/487
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
-
公开(公告)号：US20170266268A1
公开(公告)日：2017-09-21
申请号：US15437405
申请日：2017-02-20
申请人： CureVac AG
IPC分类号： A61K39/00 , A61K39/12 , A61K39/145 , A61K45/06
CPC分类号： A61K39/155 , A61K39/00 , A61K39/12 , A61K39/145 , A61K45/06 , A61K47/59 , A61K47/6455 , A61K47/6921 , A61K2039/53 , A61K2039/54 , A61K2039/55 , A61K2039/55583 , A61K2039/572 , A61K2039/575 , A61K2039/6031 , A61K2039/622 , A61P31/16 , C12N2760/16134 , C12N2760/18534 , C12N2760/18571 , Y02A50/412 , Y02A50/486 , Y02A50/487
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
-
公开(公告)号：US20160151474A1
公开(公告)日：2016-06-02
申请号：US15015458
申请日：2016-02-04
申请人： CureVac AG
IPC分类号： A61K39/00 , C12N7/00 , A61K39/145 , A61K45/06
CPC分类号： A61K39/145 , A61K39/00 , A61K39/0011 , A61K39/12 , A61K45/06 , A61K2039/53 , A61K2039/54 , A61K2039/55 , A61K2039/55505 , A61K2039/5555 , A61K2039/55555 , A61K2039/572 , A61K2039/585 , A61K2039/6031 , A61K2039/622 , A61K2039/70 , C12N7/00 , C12N2760/16134 , Y02A50/412
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
-
公开(公告)号：US20200316189A1
公开(公告)日：2020-10-08
申请号：US16910845
申请日：2020-06-24
申请人： CureVac AG
IPC分类号： A61K39/155 , A61K39/12 , A61K39/145 , A61K47/59 , A61K47/64 , A61K47/69 , A61P31/16 , A61K39/00 , A61K45/06
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
-
公开(公告)号：US20160166711A1
公开(公告)日：2016-06-16
申请号：US15048356
申请日：2016-02-19
申请人： CureVac AG
发明人： Margit SCHNEE , Thomas KRAMPS , Lothar STITZ , Benjamin PETSCH
IPC分类号： A61K48/00 , A61K9/00 , A61K39/42 , C12N7/00 , A61K39/205 , C07K14/005 , C07K16/10
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof.Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.
摘要翻译： 本发明涉及mRNA序列，其包含编码区，编码狂犬病病毒的至少一种抗原肽或蛋白质或其片段，变体或衍生物。 另外，本发明涉及包含多个mRNA序列的组合物，其包含编码区域，编码狂犬病病毒的至少一种抗原肽或蛋白质或其片段，变体或衍生物。 此外，它还公开了使用mRNA序列或包含多个mRNA序列的组合物用于制备药物组合物，特别是疫苗，例如疫苗。 用于预防或治疗狂犬病病毒感染。 本发明还描述了使用mRNA序列治疗或预防狂犬病的方法。
-
公开(公告)号：US20210030866A1
公开(公告)日：2021-02-04
申请号：US17067709
申请日：2020-10-11
申请人： CureVac AG
IPC分类号： A61K39/155 , A61K39/12 , A61K39/145 , A61K47/59 , A61K47/64 , A61K47/69 , A61P31/16 , A61K39/00 , A61K45/06
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
-
公开(公告)号：US20210023199A1
公开(公告)日：2021-01-28
申请号：US17067614
申请日：2020-10-09
申请人： CureVac AG
IPC分类号： A61K39/145 , A61K39/12 , A61K39/00 , A61K45/06 , C12N7/00
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
-
公开(公告)号：US20200268908A1
公开(公告)日：2020-08-27
申请号：US16865107
申请日：2020-05-01
申请人： CureVac AG
发明人： Margit SCHNEE , Thomas KRAMPS , Lothar STITZ , Benjamin PETSCH
IPC分类号： A61K48/00 , A61K39/205 , A61K39/12 , A61K9/00 , A61K39/42 , C07K14/005 , C07K16/10 , C12N7/00
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof.Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.
-
公开(公告)号：US20190167782A1
公开(公告)日：2019-06-06
申请号：US16273525
申请日：2019-02-12
申请人： CureVac AG
IPC分类号： A61K39/155 , A61K39/12 , A61K47/59 , A61K47/64 , A61K39/00 , A61K47/69 , A61P31/16 , A61K39/145 , A61K45/06
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
-
公开(公告)号：US20220288239A1
公开(公告)日：2022-09-15
申请号：US17746844
申请日：2022-05-17
申请人： CureVac AG
发明人： Margit SCHNEE , Thomas KRAMPS , Lothar STITZ , Benjamin PETSCH
IPC分类号： A61K48/00 , A61K39/205 , A61K39/12 , A61K9/00 , A61K39/42 , C07K14/005 , C07K16/10 , C12N7/00
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof.
Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.018 秒)
